Anti-TNF- therapies: they are all the same (aren't they?)

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

1997 • 3,152 citations

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

2003 • 1,504 citations

INHIBITORY EFFECT OF TNF$alpha; ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS

1989 • 1,137 citations

Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation

1993 • 1,073 citations

Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial

2001 • 910 citations

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

1993 • 837 citations

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

1995 • 693 citations

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

2002 • 667 citations

Localization of Tumor Necrosis Factor α in Synovial Tissues and at the Cartilage–Pannus Junction in Patients With Rheumatoid Arthritis

1991 • 585 citations

Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist

2003 • 450 citations

SERUM CYTOKINES (IL-6, TNF-α, IL-1β AND IFN-γ) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWEEN SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITY

1994 • 330 citations

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden

2002 • 259 citations

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor blockers can make sense

2003 • 229 citations

Pathogenesis of rheumatoid arthritis

1986 • 205 citations

Comparison of the efficacy of the tumour necrosis factor blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

2003 • 176 citations

What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.

2002 • 140 citations

Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept

2003 • 128 citations

PATHOGENESIS OF RHEUMATOID ARTHRITIS

2001 • 118 citations

True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin ?

2004 • 84 citations

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.

1993 • 82 citations

Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease

2003 • 79 citations

Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?

2003 • 76 citations

Behcet's syndrome: response to infliximab after failure of etanercept

2002 • 69 citations